Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Pediatric Nephrology
Erschienen in: Pediatric Nephrology 6/2022

29.05.2021 | Review

Sickle cell nephropathy: insights into the pediatric population

verfasst von: Oyindamola C. Adebayo, Lambertus P. Van den Heuvel, Wasiu A. Olowu, Elena N. Levtchenko, Veerle Labarque

Erschienen in: Pediatric Nephrology | Ausgabe 6/2022

Einloggen, um Zugang zu erhalten

Abstract

The life expectancy of individuals with sickle cell disease has increased over the years, majorly due to an overall improvement in diagnosis and medical care. Nevertheless, this improved longevity has resulted in an increased prevalence of chronic complications such as sickle cell nephropathy (SCN), which poses a challenge to the medical care of the patient, shortening the lifespan of patients by 20–30 years. Clinical presentation of SCN is age-dependent, with kidney dysfunction slowly beginning to develop from childhood, progressing to chronic kidney disease and kidney failure during the third and fourth decades of life. This review explores the epidemiology, pathology, pathophysiology, clinical presentation, and management of SCN by focusing on the pediatric population. It also discusses the factors that can modify SCN susceptibility.
Literatur
1.
Ranque B, Menet A, Diop IB, Thiam MM, Diallo D, Diop S, Diagne I, Sanogo I, Kingue S, Chelo D, Wamba G, Diarra M, Anzouan JB, N’Guetta R, Diakite CO, Traore Y, Legueun G, Deme-Ly I, BelingaS Boidy K, Kamara I, Tharaux PL, Jouven X (2014) Early renal damage in patients with sickle cell disease in sub-Saharan Africa: a multinational, prospective, cross-sectional study. Lancet Haematol 1:e64–e73PubMedCrossRef
2.
Piel FB, Patil AP, Howes RE, Nyangiri OA, Gething PW, Dewi M, Temperley WH, Williams TN, Weatherall DJ, Hay SI (2013) Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates. Lancet 381:142–151PubMedPubMedCentralCrossRef
3.
Kato GJ, Piel FB, Reid CD, Gaston MH, Ohene- Frempong K, Krishnamurti L, Smith WR, Panepinto JA, Weatherall DJ, Costa FF, Vichinsky EP (2018) Sickle cell disease. Nat Rev Dis Prim 4:1–22
4.
Taylor C, Kasztan M, Tao B, Pollock JS, Pollock DM (2019) Combined hydroxyurea and ETA receptor blockade reduces renal injury in the humanized sickle cell mouse. Acta Physiol 225:e13178
5.
6.
Andong AM, Ngouadjeu EDT, Bekolo CE, Verla VS, Nebongo D, Mboue-Djieka Y, Choukem SP (2017) Chronic complications and quality of life of patients living with sickle cell disease and receiving care in three hospitals in Cameroon: a cross-sectional study. BMC Hematol 17:7PubMedPubMedCentralCrossRef
7.
Sharpe CC, Thein SL (2014) How I treat renal complications in sickle cell disease. Blood 123:3720–3726PubMedCrossRef
8.
Mammen C, Bissonnette ML, Matsell DG (2017) Acute kidney injury in children with sickle cell disease—compounding a chronic problem. Pediatr Nephrol 32:1287–1291PubMedCrossRef
9.
10.
11.
12.
13.
14.
Olaniran KO, Eneanya D, Nigwekar SU (2019) Sickle cell nephropathy in the pediatric population. Blood Purif 47:205–213PubMedCrossRef
15.
Wesson DE (2002) The initiation and progression of sickle cell nephropathy. Kidney Int 61:2277–2286PubMedCrossRef
16.
Brewin J, Tewari S, Hannemann A, Al Balushi H, Sharpe C, Gibson JS, Rees DC (2017) Early markers of sickle nephropathy in children with sickle cell anemia are associated with red cell cation transport activity. HemaSphere 1:e2
17.
Zahr RS, Yee ME, Weaver J, Twombley K, Matar RB, Aviles D, Sreedharan R, Rheault MN, Malatesta-Muncher R, Stone H, Srivastava T, Kapur G, Baddi P, Volovelsky O, Pelletier J, Gbadegesin R, Seeherunvong W, Patel HP, Greenbaum LA (2019) Kidney biopsy findings in children with sickle cell disease: a Midwest Pediatric Nephrology Consortium study. Pediatr Nephrol 34:1435–1445PubMedCrossRef
18.
19.
Sharpe CC, Thein SL (2011) Sickle cell nephropathy - a practical approach. Br J Haematol 155:287–297PubMedCrossRef
20.
Becker AM (2011) Sickle cell nephropathy: challenging the conventional wisdom. Pediatr Nephrol 26:2099–2109PubMedCrossRef
21.
Van Avondt K, Nur E, Zeerleder S (2019) Mechanisms of haemolysis-induced kidney injury. Nat Rev Nephrol 15:671–692PubMedCrossRef
22.
Eshbach ML, Kaur A, Rbaibi Y, Tejero J, Weisz OA (2017) Hemoglobin inhibits albumin uptake by proximal tubule cells: Implications for sickle cell disease. Am J Phys Cell Physiol 312:C733–C740CrossRef
23.
Rubio-Navarro A, Sanchez-Niño MD, Guerrero-Hue M, García-Caballero C, Gutiérrez E, Yuste C, Sevillano Á, Praga M, Egea J, Román E, Cannata P, Ortega R, Cortegano I, de Andrés B, Gaspar ML, Cadenas S, Ortiz A, Egido J, Moreno JA (2018) Podocytes are new cellular targets of haemoglobin-mediated renal damage. J Pathol 244:296–310PubMedCrossRef
24.
Inusa BPD, Mariachiara L, Giovanni P, Ataga KI (2018) Sickle cell nephropathy: current understanding of the presentation, diagnostic and therapeutic challenges. In: Hematology- Latest Research and Clinical Advances. pp 156–185
25.
Ataga KI, Derebail VK, Caughey M, Elsherif L, Shen JH, Jones SK, Maitra P, Pollock DM, Cai J, Archer DR, Hinderliter AL (2016) Albuminuria is associated with endothelial dysfunction and elevated plasma endothelin-1 in sickle cell anemia. PLoS One 11:e0162652
26.
Saraf SL, Zhang X, Shah B, Kanias T, Gudehithlu KP, Kittles R, Machado RF, Arruda JAL, Gladwin MT, Singh AK, Gordeuk VR (2015) Genetic variants and cell-free hemoglobin processing in sickle cell nephropathy. Haematologica 100:1275–1284PubMedPubMedCentralCrossRef
27.
Sundd P, Gladwin MT, Novelli EM (2019) Pathophysiology of sickle cell disease. Annu Rev Pathol Mech Dis 14:263–292CrossRef
28.
29.
Nath KA, Belcher JD, Nath MC, Grande JP, Croatt AJ, Ackerman AW, Katusic ZS, Vercellotti GM (2018) Role of TLR4 signaling in the nephrotoxicity of heme and heme proteins. Am J Physiol Ren Physiol 314:F906–F914CrossRef
30.
Belcher JD, Chen C, Nguyen J, Milbauer L, Abdulla F, Alayash AI, Smith A, Nath KA, Hebbel RP, Vercellotti GM (2014) Heme triggers TLR4 signaling leading to endothelial cell activation and vaso-occlusion in murine sickle cell disease. Blood 123:377–390PubMedPubMedCentralCrossRef
31.
Ghosh S, Adisa OA, Chappa P, Tan F, Jackson KA, Archer DR, Ofori-Acquah SF (2013) Extracellular hemin crisis triggers acute chest syndrome in sickle mice. J Clin Invest 123:4809–4820PubMedPubMedCentralCrossRef
32.
33.
Da Silva Junior GB, Libório AB, De Francesco DE (2011) New insights on pathophysiology, clinical manifestations, diagnosis, and treatment of sickle cell nephropathy. Ann Hematol 90:1371–1379CrossRef
34.
Statius Van Eps LW, Schouten H, Ter Haar Romeny-Wachter CC, La Porte-Wijsman LW (1970) The relation between age and renal concentrating capacity in sickle cell disease and hemoglobin C disease. Clin Chim Acta 27:501–511PubMedCrossRef
35.
Scheinman J (1994) Sickle cell nephrology. In: Holliday M, Barratt T, Avner E (eds) Pediatric Nephrology. Williams & Wilkins, Baltimore, pp 908–914
36.
Raj VMS, Freundlich M, Hamideh D, Alvarez O, Seeherunvong W, Abitbol C, Katsoufis C, Chandar J, Ruiz P, Zilleruelo G (2014) Abnormalities in renal tubular phosphate handling in children with sickle cell disease. Pediatr Blood Cancer 61:2267–2270PubMedCrossRef
37.
Marsenic O, Couloures KG, Wiley JM (2008) Proteinuria in children with sickle cell disease. Nephrol Dial Transplant 23:715–720PubMedCrossRef
38.
Feltran LDS, Carvalhaes JTDA, Sesso R (2002) Renal complications of sickle cell disease: managing for optimal outcomes. Pediatr Drugs 4:29–36CrossRef
39.
Hariri E, Mansour A, El Alam A, Daaboul Y, Korjian S, Aoun Bahous S (2018) Sickle cell nephropathy: an update on pathophysiology, diagnosis, and treatment. Int Urol Nephrol 50:1075–1083PubMedCrossRef
40.
Wang WC, Ware RE, Miller ST, Iyer RV, Casella JF, Minniti CP, Rana S, Thornburg CD, Rogers ZR, Kalpatthi RV, Barredo JC, Brown RC, Sarnaik SA, Howard TH, Wynn LW, Kutlar A, Armstrong FD, Files BA, Goldsmith JC, Waclawiw MA, Huang X, Thompson BW (2011) Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet 377:1663–1672PubMedPubMedCentralCrossRef
41.
Aloni MN, Ngiyulu RM, Ekulu PM, Mbutiwi FIN, Makulo JR, Gini-Ehungu JL, Nseka NM, Lepira FB (2017) Glomerular hyperfiltration is strongly correlated with age in Congolese children with sickle cell anaemia. Acta Paediatr Int J Paediatr 106:819–824CrossRef
42.
Aloni MN, Mabidi JLL, Ngiyulu RM, Ekulu PM, Mbutiwi FI, Makulo JR, Sumaili EK, Gini-Ehungu JL, Nsibu CN, Nseka NM, Lepira FB (2017) Prevalence and determinants of microalbuminuria in children suffering from sickle cell anemia in steady state. Clin Kidney J 10:479–486PubMedPubMedCentralCrossRef
43.
Bernstein J, Whitten C (1960) A histologic appraisal of the kidney in sickle cell anemia. Arch Pathol 70:407–418PubMed
44.
Bhathena DB, Sondheimer JH (1991) The glomerulopathy of homozygous sickle hemoglobin (SS) disease: morphology and pathogenesis. J Am Soc Nephrol 1:1241–1252PubMedCrossRef
45.
Van Eps LWS, Schouten H, La Porte-Wijsman LW, Struyker Boudier AM (1967) The influence of red blood cell transfusions on the hyposthenuria and renal hemodynamics of sickle cell anemia. Clin Chim Acta 17:449–461CrossRef
46.
Dharnidharka VR, Dabbagh S, Atiyeh B, Simpson P, Sarnaik S (1998) Prevalence of microalbuminuria in children with sickle cell disease. Pediatr Nephrol 12:475–478PubMedCrossRef
47.
Guasch A, Cua M, Mitch WE (1996) Early detection and the course of glomerular injury in patients with sickle cell anemia. Kidney Int 49:786–791PubMedCrossRef
48.
McBurney PG, Hanevold CD, Hernandez CM, Waller JL, McKie KM (2002) Risk factors for microalbuminuria in children with sickle cell anemia. J Pediatr Hematol Oncol 24:473–477PubMedCrossRef
49.
Guasch A, Cua M, You W, Mitch WE (1997) Sickle cell anemia causes a distinct pattern of glomerular dysfunction. Kidney Int 51:826–833PubMedCrossRef
50.
Day TG, Drasar ER, Fulford T, Sharpe CC, Thein SL (2012) Association between hemolysis and albuminuria in adults with sickle cell anemia. Haematologica 97:201–205PubMedPubMedCentralCrossRef
51.
Drawz P, Ayyappan S, Nouraie M, Saraf S, Gordeuk V, Hostetter T, Gladwin MT, Little J, (, (2016) Kidney disease among patients with sickle cell disease, hemoglobin SS and SC. Clin J Am Soc Nephrol 11:207–215PubMedCrossRef
52.
Bakir AA, Hathiwala SC, Ainis H, Hryhorczuk DO, Rhee HL, Levy PS, Dunear G (1987) Prognosis of the nephrotic syndrome in sickle glomerulopathy. Am J Nephrol 7:110–115PubMedCrossRef
53.
Powars DR, Elliott-Mills DD, Chan L, Niland J, Hiti AL, Opas LM, Johnson C (1991) Chronic renal failure in sickle cell disease: risk factors, clinical course, and mortality. Ann Intern Med 115:614–620PubMedCrossRef
54.
Bodas P, Huang A, O’Riordan MA, Sedor JR, Dell KM (2013) The prevalence of hypertension and abnormal kidney function in children with sickle cell disease -a cross sectional review. BMC Nephrol 14:2–7CrossRef
55.
Powars DR, Chan LS, Hiti A, Ramicone E, Johnson C (2005) Outcome of sickle cell anemia: a 4-decade observational study of 1056 patients. Medicine (Baltimore) 84:363–376CrossRef
56.
Burdmann EA, Jha V (2017) Acute kidney injury due to tropical infectious diseases and animal venoms: a tale of 2 continents. Kidney Int 91:1033–1046PubMedCrossRef
57.
Van Wolfswinkel ME, Koopmans LC, Hesselink DA, Hoorn EJ, Koelewijn R, Van Hellemond JJ, Van Genderen PJJ (2016) Neutrophil gelatinase-associated lipocalin (NGAL) predicts the occurrence of malaria-induced acute kidney injury. Malar J 15:464PubMedPubMedCentralCrossRef
58.
Amoura A, Moktefi A, Halfon M, Karras A, Rafat C, Gibier JB, Gleeson PJ, Servais A, Argy N, Maillé P, Belenfant X, Gueutin V, Delpierre A, Tricot L, El Karoui K, Jourde-Chiche N, Houze S, Sahali D, Audard V (2020) Malaria, collapsing glomerulopathy, and focal and segmental glomerulosclerosis. Clin J Am Soc Nephrol 15:964–972PubMedPubMedCentralCrossRef
59.
Ouma BJ, Ssenkusu JM, Shabani E, Datta D, Opoka RO, Idro R, Bangirana P, Park G, Joloba ML, Kain KC, John CC, Conroy AL (2020) Endothelial activation, acute kidney injury, and cognitive impairment in pediatric severe malaria. Crit Care Med 48:e734–e743PubMedPubMedCentralCrossRef
60.
61.
62.
Tewari S, Brousse V, Piel FB, Menzel S, Rees DC (2015) Environmental determinants of severity in sickle cell disease. Haematologica 100:1108–1116PubMedPubMedCentralCrossRef
63.
Power-Hays A, Li S, Mensah A, Sobota A (2020) Universal screening for social determinants of health in pediatric sickle cell disease: a quality-improvement initiative. Pediatr Blood Cancer 67:e28006PubMed
64.
65.
Raphael JL (2020) Addressing social determinants of health in sickle cell disease: the role of Medicaid policy. Pediatr Blood Cancer 67:e28202PubMedCrossRef
66.
Naik RP, Derebail VK (2017) The spectrum of sickle hemoglobin-related nephropathy: from sickle cell disease to sickle trait. Expert Rev Hematol 10:1087–1094PubMedPubMedCentralCrossRef
67.
Colombatti R, Maschietto N, Varotto E, Grison A, Grazzina N, Meneghello L, Teso S, Carli M, Milanesi O, Sainati L (2010) Pulmonary hypertension in sickle cell disease children under 10 years of age. Br J Haematol 150:601–609PubMedCrossRef
68.
Aygun B, Mortier NA, Smeltzer MP, Hankins JS, Ware RE (2011) Glomerular hyperfiltration and albuminuria in children with sickle cell anemia. Pediatr Nephrol 26:1285–1290PubMedPubMedCentralCrossRef
69.
Geard A, Pule GD, Chetcha Chemegni B, Ngo Bitoungui VJ, Kengne AP, Chimusa ER, Wonkam A (2017) Clinical and genetic predictors of renal dysfunctions in sickle cell anaemia in Cameroon. Br J Haematol 178:629–639PubMedPubMedCentralCrossRef
70.
Strumph K, Hafeman M, Ranabothu S, Gomes W, Benitez S, Kaskel F, Manwani D, Mahgerefteh J (2021) Nocturnal hypertension associated with stroke and silent cerebral infarcts in children with sickle cell disease. Pediatr Blood Cancer 68:e28883
71.
Moodalbail DG, Falkner B, Keith SW, Mathias RS, Araya CE, Zaritsky JJ, Stuart MJ (2018) Ambulatory hypertension in a pediatric cohort of sickle cell disease. J Am Soc Hypertens 12:542–550PubMedPubMedCentralCrossRef
72.
Shatat IF, Jakson SM, Blue AE, Johnson MA, Orak JK, Kalpatthi R (2013) Masked hypertension is prevalent in children with sickle cell disease: a Midwest Pediatric Nephrology Consortium study. Pediatr Nephrol 28:115–120PubMedCrossRef
73.
Becker AM, Goldberg JH, Henson M, Ahn C, Tong L, Baum M, Buchanan GR (2014) Blood pressure abnormalities in children with sickle cell anemia. Pediatr Blood Cancer 61:518–522PubMedCrossRef
74.
Asnani MR, Fraser RA, Reid ME (2011) Higher rates of hemolysis are not associated with albuminuria in Jamaicans with sickle cell disease. PLoS One 6:e18863PubMedPubMedCentralCrossRef
75.
Haymann JP, Stankovic K, Levy P, Avellino V, Tharaux PL, Letavernier E, Grateau G, Baud L, Girot R, Lionnet F (2010) Glomerular hyperfiltration in adult sickle cell anemia: a frequent hemolysis associated feature. Clin J Am Soc Nephrol 5:756–761PubMedPubMedCentralCrossRef
76.
Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, Klug PP (1994) Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 330:1639–1644PubMedCrossRef
77.
Guasch A, Navarrete J, Nass K, Zayas CF (2006) Glomerular involvement in adults with sickle cell hemoglobinopathies: prevalence and clinical correlates of progressive renal failure. J Am Soc Nephrol 17:2228–2235PubMedCrossRef
78.
Ballas SK (2001) Effect of α-globin genotype on the pathophysiology of sickle cell disease. Pediatr Pathol Mol Med 20:277–286
79.
Steinberg MH, Barton F, Castro O, Pegelow CH, Ballas SK, Kutlar A, Orringer E, Bellevue R, Olivieri N, Eckman J, Varma M, Ramirez G, Adler B, Smith W, Carlos T, Ataga K, DeCastro L, Bigelow C, Saunthararajah Y, Telfer M, Vichinsky E, Claster S, Shurin S, Bridges K, Waclawiw M, Bonds D, Terrin M (2003) Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. J Am Med Assoc 289:1645–1651CrossRef
80.
Toole JFO, Schilling W, Kunze D, Madhavan SM, Konieczkowski M, Gu Y, Luo L, Wu Z, Bruggeman LA, Sedor JR (2018) ApoL1 overexpression drives variant-independent cytotoxicity. J Am Soc Nephrol 29:869–879CrossRef
81.
Ekulu PM, Nkoy AB, Betukumesu DK, Aloni MN, Makulo JRR, Sumaili EK, Mafuta EM, Elmonem MA, Arcolino FO, Kitetele FN, Lepira FB, van den Heuvel LP, Levtchenko EN (2019) APOL1 risk genotypes are associated with early kidney damage in children in sub-Saharan Africa. Kidney Int Rep 4:930–938PubMedPubMedCentralCrossRef
82.
Genovese G, Friedman DJ, Ross MD, Lecordier L, Uzureau P, Freedman BI, Bowden DW, Langefeld CD, Oleksyk TK, Uscinski Knob AL, Bernhardy AJ, Hicks PJ, Nelson GW, Vanhollebeke B, Winkler CA, Kopp JB, Pays E, Pollak MR (2010) Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 329:841–845PubMedPubMedCentralCrossRef
83.
Kopp JB, Nelson GW, Sampath K, Johnson RC, Genovese G, An P, Friedman D, Briggs W, Dart R, Korbet S, Mokrzycki MH, Kimmel PL, Limou S, Ahuja TS, Berns JS, Fryc J, Simon EE, Smith MC, Trachtman H, Michel DM, Schelling JR, Vlahov D, Pollak M, Winkler CA (2011) APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol 22:2129–2137PubMedPubMedCentralCrossRef
84.
Ekulu PM, Nkoy AB, Adebayo OC, Kazadi OK, Aloni MN, Arcolino FO, Ngiyulu RM, Gini JLE, Lepira FB, Van den Heuvel LP, Levtchenko EN (2021) A focus on the association of Apol1 with kidney disease in children. Pediatr Nephrol 36:777–788PubMedCrossRef
85.
Kormann R, Jannot AS, Narjoz C, Ribeil JA, Manceau S, Delville M, Joste V, Prié D, Pouchot J, Thervet E, Courbebaisse M, Arlet JB (2017) Roles of APOL1 G1 and G2 variants in sickle cell disease patients: kidney is the main target. Br J Haematol 179:326–335CrossRef
86.
Madhavan SM, O’Toole JF, Konieczkowski M, Ganesan S, Bruggeman LA, Sedor JR (2011) APOL1 localization in normal kidney and nondiabetic kidney disease. J Am Soc Nephrol 22:2119–2128PubMedPubMedCentralCrossRef
87.
Ma L, Shelness GS, Snipes JA, Murea M, Antinozzi PA, Cheng D, Saleem MA, Satchell SC, Banas B, Mathieson PW, Kretzler M, Hemal AK, Rudel LL, Petrovic S, Weckerle A, Pollak MR, Ross MD, Parks JS, Freedman BI (2015) Localization of APOL1 protein and mRNA in the human kidney: nondiseased tissue, primary cells, and immortalized cell lines. J Am Soc Nephrol 26:339–348PubMedCrossRef
88.
Uzureau S, Lecordier L, Uzureau P, Hennig D, Graversen JH, Homblé F, Mfutu PE, Oliveira Arcolino F, Ramos AR, La Rovere RM, Luyten T, Vermeersch M, Tebabi P, Dieu M, Cuypers B, Deborggraeve S, Rabant M, Legendre C, Moestrup SK, Levtchenko E, Bultynck G, Erneux C, Pérez-Morga D, Pays E (2020) APOL1 C-terminal variants may trigger kidney disease through interference with APOL3 control of actomyosin. Cell Rep 30:3821-3836.e13PubMedPubMedCentralCrossRef
89.
90.
Anderson S, Meyer TW, Rennke HG, Brenner BM (1985) Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin Invest 76:612–619PubMedPubMedCentralCrossRef
91.
Falk RJ, Scheinman J, Phillips G, Orringer E, Johnson A, Jennette JC (1992) Prevalence and pathologic features of sickle cell nephropathy and response to inhibition of angiotensin-converting enzyme. N Engl J Med 326:910–915PubMedCrossRef
92.
Fitzhugh CD, Wigfall DR, Ware RE (2005) Enalapril and hydroxyurea therapy for children with sickle nephropathy. Pediatr Blood Cancer 45:982–985PubMedCrossRef
93.
Aoki RY, Saad STO (1995) Enalapril reduces the albuminuria of patients with sickle cell disease. Am J Med 98:432–435PubMedCrossRef
94.
McKie KT, Hanevold CD, Hernandez C, Waller JL, Ortiz L, McKie KM (2007) Prevalence, prevention, and treatment of microalbuminuria and proteinuria in children with sickle cell disease. J Pediatr Hematol Oncol 29:140–144PubMedCrossRef
95.
Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, McMahon RP, Bonds DR (1995) Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med 332:1317–1322PubMedCrossRef
96.
Alvarez O, Montane B, Lopez G, Wilkinson J, Miller T (2006) Early blood transfusions protect against microalbuminuria in children with sickle cell disease. Pediatr Blood Cancer 47:71–76PubMedCrossRef
97.
De Jong PE, Van Eps LWS (1985) Sickle cell nephropathy: new insights into its pathophysiology. Kidney Int 27:711–717PubMedCrossRef
98.
Becton LJ, Kalpatthi RV, Rackoff E, Disco D, Orak JK, Jackson SM, Shatat IF (2010) Prevalence and clinical correlates of microalbuminuria in children with sickle cell disease. Pediatr Nephrol 25:1505–1511PubMedCrossRef
99.
Warady BA, Sullivan EK (1998) Renal transplantation in children with sickle cell disease: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Pediatr Transplant 2:130–133PubMed
Metadaten
Titel
Sickle cell nephropathy: insights into the pediatric population
verfasst von
Oyindamola C. Adebayo
Lambertus P. Van den Heuvel
Wasiu A. Olowu
Elena N. Levtchenko
Veerle Labarque
Publikationsdatum
29.05.2021
Verlag
Springer Berlin Heidelberg
Erschienen in
Pediatric Nephrology / Ausgabe 6/2022
Print ISSN: 0931-041X
Elektronische ISSN: 1432-198X
DOI
https://doi.org/10.1007/s00467-021-05126-4

Weitere Artikel der Ausgabe 6/2022

Pediatric Nephrology 6/2022 Zur Ausgabe

Clinical Quiz

Chediak Higashi syndrome with acute kidney injury: Answers

Guidelines

Acute kidney injury in pediatric hematopoietic cell transplantation: critical appraisal and consensus

Clinical Quiz

A boy with purpura and generalized edema: Answers

Original Article

Development of a patient-reported outcome measure for the assessment of symptom burden in pediatric chronic kidney disease (PRO-Kid)

Publisher Correction

Correction to: Non-lupus full-house nephropathy—immune dysregulation as a rare cause of pediatric nephrotic syndrome: Answers

Brief Report

The roles of homocysteinemia and methylmalonic acidemia in kidney injury in atypical hemolytic uremic syndrome caused by cobalamin C deficiency

Neu im Fachgebiet Pädiatrie

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

Frühe Hypertonie erhöht späteres kardiovaskuläres Risiko

16.05.2024 Arterielle Hypertonie in der Pädiatrie Nachrichten

Wie wichtig es ist, pädiatrische Patienten auf Bluthochdruck zu screenen, zeigt eine kanadische Studie: Hypertone Druckwerte in Kindheit und Jugend steigern das Risiko für spätere kardiovaskuläre Komplikationen.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise